This trispecific T cell engager incorporates CD28 co-stimulation and has shown potent antitumor activity in preclinical models including small cell lung cancer. These cancers are notoriously hard ...

285 [1147-59]). T cells isolated from TN patients demonstrated a superior proliferation ability upon either acute or chronic in vitro activation with anti-CD3 and anti-CD28 antibodies, and were ...

For short term TCR stimulation, CD4SP thymocytes and mature naive T cells were incubated with 2 µg/mL anti-mouse CD3 and 1 µg/mL anti-mouse CD28 on ice for 20 min, followed by cross-linking for 10 min ...

1-9 These therapies incorporate either a 4-1BB (CD137) or a CD28 intracellular costimulatory domain to enhance T-cell activation and persistence. Despite these advancements, more than 50% of ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response ...

After spending years tracing the origin and migration pattern of an unusual type of immune cell in mice, researchers headed by a team at The Ohio State University College of Medicine have shown ...

Inhibition of PRC2 enables self-renewal of blastoid-competent naive pluripotent stem cells from chimpanzee. Cell Stem Cell , 2025; 32 (4): 627 DOI: 10.1016/j.stem.2025.02.002 Cite This Page : ...

where they undergo positive and negative selection to produce a nonself-binding T-cell antigen receptor, and emerge as naive, single, positive T cells. After encountering antigen in the periphery ...

French cell therapy company Celyad is also working in the area, its lead candidate CYAD-01 is an autologous CAR-T NKG2D therapy for use in haematological and solid cancers.

Yescarta – a CD19-directed genetically modified autologous T-cell immunotherapy investigated in the ZUMA-1 trial – is the first chimeric antigen receptor (CAR) T-cell therapy recommended for ...